Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

of Novo Nordisk "Site Odense" in Kroghs park in Odense, Denmark, on December 16, 2024. (Photo by Mads Claus Rasmussen / Ritzau Scanpix / AFP) / Denmark OUT (Photo by MADS CLAUS RASMUSSEN/Ritzau ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk A/S (NVO) investors were hit by a train as the leading diabetes and obesity drugs maker's recent CagriSema study didn't impress as its performance came in markedly below its ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit," he ...

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.